Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 57 of 6351
-
Tiny implant in vein could keep heart failure patients out of hospital
Disease control Recruiting nowThis is an international, multi-center, prospective, randomized, open-label blinded endpoint study designed to demonstrate that use of the FIRE1 NORM™ System in the management of New York Heart Association Class II/III HF patients is superior for reducing the combined endpoint of…
Sponsor: Foundry Innovation & Research 1, Limited (FIRE1) • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can a Triple-Drug combo erase rectal tumors before surgery?
Disease control Recruiting nowObservation and evaluation of the safety and efficacy of PD-1 antibody combined with IBI310 and neoadjuvant chemotherapy in the treatment of locally advanced rectal cancer Primary objectives: Pathological complete response (pCR) rate; Secondary objectives: Treatment-related a…
Phase 2 • Sponsor: Xijing Hospital • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a Two-Drug attack reach cancer hiding in the brain?
Disease control Recruiting nowThe goal of this clinical trial is to learn whether amivantamab combined with intrathecal pemetrexed is safe and may help treat leptomeningeal metastasis in adults with EGFR-mutant lung adenocarcinoma. Leptomeningeal metastasis occurs when cancer cells spread to the membranes sur…
Phase 1/2 • Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
One-time gene therapy aims to restore hearing in kids with genetic deafness
Disease control Recruiting nowSkylark Bio is conducting a study of an investigational new drug called SKY-GJB2 and its delivery device, the SKY-CAT. SKY-GJB2 is a gene therapy that is being developed to treat children who have hearing loss due to changes in the GJB2 gene (also referred to as Connexin 26). The…
Phase 1/2 • Sponsor: Skylark Bio Inc. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Hope for rare bone disease: first drug trial launches
Disease control Recruiting nowJansen s Metaphyseal Chondrodysplasia (JMC) is a very rare disorder with only approximately 30 people known to have the disease worldwide. It is caused by parathyroid hormone 1 receptor (PTH1R) variants leading to constitutive activation of the receptor for parathyroid hormone (P…
Phase 1/2 • Sponsor: National Institute of Dental and Craniofacial Research (NIDCR) • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Heated chemo during surgery could boost colon cancer survival
Disease control Recruiting nowThe main objective of this randomized and controlled trial is to determine whether the use of a proactive strategy, systemic neoadjuvant treatment (FOLFOX) with or without hyperthermic intraperitoneal chemoterapy (HIPEC) with mitomycin C followed by postoperative systemic adjuvan…
Phase 3 • Sponsor: Maimónides Biomedical Research Institute of Córdoba • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Massive vaccine trial aims to stop debilitating chikungunya virus
Vaccine Recruiting nowStudy EBSI-CV-317-007 is a field study to evaluate the efficacy, immunogenicity, and safety of CHIKV VLP vaccine. The study was designed using infectious disease models and advanced analytics to guide region and clinical site prioritization, define the timing of study activities,…
Phase 3 • Sponsor: Bavarian Nordic • Aim: Vaccine
Last updated Jul 01, 2026 00:00 UTC
-
New triple therapy aims to stop liver cancer from coming back
Disease control Not yet recruitingThis study aims to explore the value of the 'HAIC Apatinib Camrelizumab' triple regimen for perioperative treatment of resectable hepatocellular carcinoma. The study adopts a multicenter, randomized, open-label, controlled design and plans to enroll 208 patients, randomly assigne…
Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New CAR T-Cell therapy aims to outperform current treatment for aggressive lymphoma
Disease control Recruiting nowThe goal of this clinical study is to compare the study drug KITE-753 versus axicabtagene ciloleucel (axi-cel) in adult participants with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) after one prior line of therapy. The primary objective of this study is to evaluate…
Phase 3 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New hope for hard-to-treat pancreatic cancer: targeted drug combo enters phase 3 trial
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to placebo in combination with chemotherapy.
Phase 3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New combo drug CagriSema aims to outperform semaglutide for obesity
Disease control Recruiting nowThis clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participan…
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New drug targets breast cancer in the brain
Disease control Recruiting nowThe purpose of this study is to assess the efficacy and safety of RO7771950 in combination with trastuzumab and capecitabine, compared to tucatinib in combination with trastuzumab and capecitabine.
Phase 2/3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug linvoseltamab aims to stall multiple myeloma in High-Risk patients
Disease control Recruiting nowThis study is researching an experimental drug called linvoseltamab (also called "study drug") compared to another drug called daratumumab, in participants with Smoldering Multiple Myeloma (SMM), who are at a High Risk (HR) of developing active multiple myeloma. The aim of this …
Phase 3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
AI biomarker may reveal who responds to esophageal cancer immunotherapy
Diagnosis OngoingThe intratumoral microbiota is a key modulator of the tumor immune microenvironment. This study aims to clinically validate a novel, AI-driven digital pathology biomarker-the Microbial-Sensory Coupling (MSC) index-which measures the spatial proximity between the intratumoral bact…
Sponsor: Peking University Cancer Hospital & Institute • Aim: Diagnosis
Last updated Aug 06, 2026 00:00 UTC
-
New combo therapy aims to boost survival in tough rectal cancer
Disease control Recruiting nowTo explore the efficacy and safety of an intensified treatment regimen consisting of short-course radiotherapy followed by mFOLFOX6 chemotherapy combined with precise targeted therapy (based on RAS/BRAF status: cetuximab for wild-type, bevacizumab for mutant) and a PD-1 monoclona…
Phase 3 • Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Can electric pulses boost immunotherapy against tough liver tumors?
Disease control Recruiting nowThis is a prospective, randomized, controlled, exploratory Phase II clinical study. Approximately 60 eligible patients with hepatocellular carcinoma and portal vein tumor thrombus who have received three cycles of target-immunotherapy induction and have non-progressive disease wi…
Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New hope for tough leukemia: MK-1045 takes on standard therapy
Disease control Recruiting nowResearchers are looking for new ways to treat people with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) that is CD19 positive using a medicine called MK-1045. MK-1045 is an immunotherapy, which is a treatment that helps the immune system fight cancer. Thi…
Phase 2/3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
MDMA therapy trial targets PTSD and alcoholism in veterans
Disease control Recruiting nowThe study investigators are conducting the first randomized placebo-controlled trial of MDMA-assisted therapy with a comorbid sample of military Veterans with a co-occurring diagnosis of Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD). This novel experimental…
Phase 2/3 • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Engineered immune cells take aim at a common pancreatic cancer mutation
Disease control Recruiting nowESSIGHT-HJG-ES502-01 is a dose-escalation study of ES502 in patients with advanced pancreatic cancer. The study will enroll patients with advanced, RAS G12V positive pancreatic cancer who have no effective treatment options available (HLA genotyping required).
Early phase 1 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
One shot to stop RSV: landmark trial for indigenous kids
Prevention Not yet recruitingRSV is a leading cause of severe respiratory illness and hospitalisation for young children, with particularly high rates of RSV respiratory infection observed amongst Aboriginal and Torres Strait Islander children living in Australia's Northern Territory. The goal of this clinic…
Phase 4 • Sponsor: Menzies School of Health Research • Aim: Prevention
Last updated Jun 27, 2026 12:31 UTC